Hirotaka Nishikiori
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hirotaka Nishikiori has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Gen Yamada
Department of Respiratory Medicine, Teine Keijinkai Hospital, 1-12 Maeda, Teineku, Sapporo, Hokkaido 006-8555, Japan
1 shared publication Hirofumi Chiba
Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan
1 shared publication- Hirofumi Chiba
Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan
1 shared publication Hirofumi Ohnishi
Department of Public Health, Sapporo Medical University School of Medicine, Sapporo, Japan
1 shared publication- Hiroki Takahashi
Third Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
1 shared publication Kenichi Hirota
Department of Medical Information Planning, Sapporo Medical University Hospital, Sapporo, Japan
1 shared publication
Latest Publications
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , OA1211
Validation of the artificial intelligence software to detect chronic fibrosing interstitial lung diseases in chest X-ray
Background: Early use of anti-fibrotic drugs for idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung diseases (ILD) is recommended to restrain deterioration of the respiratory function and prevent the acute exacerbation. However, it is challenging to find patients with ILD in their early stage with the chest X-ray examination. Recently, we developed an artificial intelligence (AI) software to help doctors detect chronic fibrosing ILD (CF-ILD). We currently validated the detection capability of this program using over 1200 chest X-ray images confirmed whether they have CF-ILD or not on the computed tomography (CT). Method: We identified consecutive chest X-ray images of patients who visited Sapporo Medical University Hospital from Jan 1 to Dec 31, 2019 and took chest X-ray and CT in the same day. We let the AI software interpret chest X-ray images and calculate the “likelihood score” for CF-ILD. CT images were interpreted by four specialists of pulmonary radiography and classified into normal, CF-ILD suspected/proven and having other abnormal findings. We investigated the detecting capability of AI software by AUC of ROC curve made from the sensitivity and false positive rate. Result: We identified 1280 patients and images, which included 352 with CF-ILD, 666 with other abnormal findings and 310 without abnormal findings. The AUC of ROC curve was 0.889 among CF-ILD-positive and CF-ILD-negative and 0.960 among CF-ILD-positive and no abnormal findings. Conclusion: Our AI software to detect CF-ILD in the chest X-ray showed a good detection performance.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , OA1211
Validation of the artificial intelligence software to detect chronic fibrosing interstitial lung diseases in chest X-ray
Background: Early use of anti-fibrotic drugs for idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung diseases (ILD) is recommended to restrain deterioration of the respiratory function and prevent the acute exacerbation. However, it is challenging to find patients with ILD in their early stage with the chest X-ray examination. Recently, we developed an artificial intelligence (AI) software to help doctors detect chronic fibrosing ILD (CF-ILD). We currently validated the detection capability of this program using over 1200 chest X-ray images confirmed whether they have CF-ILD or not on the computed tomography (CT). Method: We identified consecutive chest X-ray images of patients who visited Sapporo Medical University Hospital from Jan 1 to Dec 31, 2019 and took chest X-ray and CT in the same day. We let the AI software interpret chest X-ray images and calculate the “likelihood score” for CF-ILD. CT images were interpreted by four specialists of pulmonary radiography and classified into normal, CF-ILD suspected/proven and having other abnormal findings. We investigated the detecting capability of AI software by AUC of ROC curve made from the sensitivity and false positive rate. Result: We identified 1280 patients and images, which included 352 with CF-ILD, 666 with other abnormal findings and 310 without abnormal findings. The AUC of ROC curve was 0.889 among CF-ILD-positive and CF-ILD-negative and 0.960 among CF-ILD-positive and no abnormal findings. Conclusion: Our AI software to detect CF-ILD in the chest X-ray showed a good detection performance.
- Open Access
- 14 March 2013
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 7 (1) , 72
Systemic lymph node tuberculosis presenting with an aseptic psoas abscess caused by a paradoxical reaction after nine months of antituberculosis treatment: a case report
A paradoxical reaction during antituberculosis treatment is defined as the worsening of pre-existing tuberculosis lesions or the appearance of a new tuberculosis lesion in patients whose clinical symptoms improved with antituberculosis treatment. The median onset time to the development of a paradoxical response has been reported to be about 60 days after the start of treatment. We report the case of a patient with a paradoxical reaction presenting as a psoas abscess after nine months of antituberculosis treatment. To the best of our knowledge, this manifestation has not previously been reported.
- 14 March 2013
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 7 (1) , 72
Open AccessSystemic lymph node tuberculosis presenting with an aseptic psoas abscess caused by a paradoxical reaction after nine months of antituberculosis treatment: a case report
A paradoxical reaction during antituberculosis treatment is defined as the worsening of pre-existing tuberculosis lesions or the appearance of a new tuberculosis lesion in patients whose clinical symptoms improved with antituberculosis treatment. The median onset time to the development of a paradoxical response has been reported to be about 60 days after the start of treatment. We report the case of a patient with a paradoxical reaction presenting as a psoas abscess after nine months of antituberculosis treatment. To the best of our knowledge, this manifestation has not previously been reported.